Compare · ABT vs SEPN
ABT vs SEPN
Side-by-side comparison of Abbott Laboratories (ABT) and Septerna Inc. (SEPN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SEPN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.35B, about 95.3x SEPN ($1.90B).
- SEPN has been more active in the news (11 items in the past 4 weeks vs 9 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 11 for SEPN).
- Company
- Abbott Laboratories
- Septerna Inc.
- Price
- -
- -
- Market cap
- $181.35B
- $1.90B
- 1M return
- +0.63%
- -
- 1Y return
- -19.49%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 9
- 11
- Recent ratings
- 25
- 11
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott Laboratories filed SEC Form 8-K: Leadership Update
- New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season
- EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)
- SEC Form 10-Q filed by Abbott Laboratories
- Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke
- Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
- Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
- Abbott Labs downgraded by Argus
- Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
- Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Latest SEPN
- Chief Executive Officer Finer Jeffrey exercised 18,500 shares at a strike of $2.76 and sold $807,015 worth of shares (18,500 units at $43.62) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.
- Director Ezekowitz Alan sold $3,934,363 worth of shares (81,820 units at $48.09) as part of a pre-agreed trading plan, decreasing direct ownership by 70% to 35,600 units (SEC Form 4)
- SEC Form 144 filed by Septerna Inc.
- SEC Form 144 filed by Septerna Inc.
- SEC Form 10-Q filed by Septerna Inc.
- Septerna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results
- Septerna Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting